Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Mahmoud El-Bendary, Sherief Abd-Elsalam, Tamer Elbaz, Wafaa El-Akel, Ahmed Cordie, Tamer Elhadidy, Hatem Elalfy, Khaled Farid, Mohamed Elegezy, Adel El-Badrawy, Mustafa Neamatallah, Mohamed Abd Elghafar, Marwa Salama, Mohamed AbdAllah, Mahmoud Essam, Mostafa El-Shazly & Gamal Esmat. (2022) RETRACTED ARTICLE: Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Review of Anti-infective Therapy 20:2, pages 291-295.
Read now
Read now
Tamer A Elbedewy, Mohamed A Elsebaey, Samah A Elshweikh, Heba Elashry & Sherief Abd-Elsalam. (2019) Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia. Therapeutics and Clinical Risk Management 15, pages 269-274.
Read now
Read now
Samar K. Darweesh, Kadry Elsaeed, Heba Omar, Maissa El Raziky, Wafaa Elakel, Magdy Elserafy, Sohier Ahmed Ismail, Ahmed A. Gomaa, Mai Mehrez, Mahamed El Kassas, Mohamed Abdullah, Mohammed Kamal Shaker, Gamal Esmat, Yehia El shazly, Wahid Doss & Imam Waked. (2019) High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study. Expert Review of Gastroenterology & Hepatology 13:9, pages 907-914.
Read now
Read now
Ahmed Mohamed Saleh, Essam Ali Hassan, Ahmed Ali Gomaa, Tamer Mahmoud El Baz, Mohamed El-Abgeegy, Mohamed Ismail Seleem, Yousry Esam-Eldin Abo-amer, Heba Fadl Elsergany, Eman Ibrahim El-Desoki Mahmoud & Sherief Abd-Elsalam. (2019) Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt. Infection and Drug Resistance 12, pages 2277-2282.
Read now
Read now
Yousry Esam-Eldin Abo-Amer, Sherief Abd-Elsalam, Hazim Eldosoky, Amira K ELShenawy, Shereen Awny, Waleed Elagawy, Mohamed El Abgeegy, Heba Fadl Elsergany, Heba Elashry & Manal Saad Negm. (2018) Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt. Infection and Drug Resistance 11, pages 2435-2441.
Read now
Read now
Ahmed Khaled Tawfik, Amal Helmy, Mohamed Yousef, Sabry Abou-Saif, Abdelrahman Kobtan, Eman Asaad & Sherief Abd-Elsalam. (2018) Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications. Hepatic Medicine: Evidence and Research 10, pages 87-93.
Read now
Read now
Ahmed Khaled Tawfik, Ahmed Mustafa Amin, Mohamed Yousef, Noha Mohamed El-sayd, Heba Elashry, Mahmoud Elkadeem & Sherief Abd-Elsalam. (2018) IL-1α correlates with severity of hepatitis C virus-related liver diseases. Journal of Inflammation Research 11, pages 289-295.
Read now
Read now
Articles from other publishers (32)
Wafaa M. Ezzat, Khalda S. Amr, Salwa Tawfeek, Hassan Elbatae, Eman A. Bayomi, Ahmed Heiba & Yasser Elhosary. (2024) Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment. BMC Infectious Diseases 24:1.
Crossref
Crossref
Karim Nader, Amro Shetta, Sameh Saber & Wael Mamdouh. (2023) The potential of carbon-based nanomaterials in hepatitis C virus treatment: a review of carbon nanotubes, dendrimers and fullerenes. Discover Nano 18:1.
Crossref
Crossref
Nabil Debzi, Saadi Berkane, Chafika Manouni, Nassima Amani, Sonia Hemmam, Mohamed Yousfi, Ayoub Taleb, Nawal Guessab, Ahlem Sarah Moulay Brahim, Sarah Helal, Ismahane Benbitour, Lynda Noual, Rafik Kerbouche, Ibtissem Ouled Cheikh, Othmane Drir, Hibat Allah Belimi, Samir Gourari, Issam Frigga, Ahmed Kassah-laouar, Mouna Khaberi & Nawal Afredj. (2023) Efficacy of Sofosbuvir/Daclatasvir in a Single Tablet for Treating Chronic Viral Hepatitis C. Journal of Clinical Pharmacy and Therapeutics 2023, pages 1-9.
Crossref
Crossref
Islam Shah, Nayab Munib, Aliena Badshah & Wazir Mohammad. (2023) Frequency of Sustained Virologic Response in Hepatitis C Positive, Treatment Naïve Patients on Sofosbuvir and Daclatasvir. Journal of Gandhara Medical and Dental Science 10:3, pages 22-26.
Crossref
Crossref
Attiya S Rahman, Muhammad Amir, Qaiser Jamal, Mehwish Riaz, Komal Fareed & Muhammad Siddiqui. (2023) End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir. Cureus.
Crossref
Crossref
Ahmed H. Moustafa, Heba F. Pasha, Manar A. Abas & Adel M. Aboregela. (2022) The ameliorating role of sofosbuvir and daclatasvir on thioacetamide-induced kidney injury in adult albino rats. Anatomy & Cell Biology 56:1, pages 109-121.
Crossref
Crossref
Nipun Jain, Ravinder Garg, Gagan Preet Singh, Sarabjot Kaur, Sumit Pal Singh Chawla & Preeti Padda. (2023) Assessment of Factors Affecting Response of Direct-Acting Antivirals in Chronic Hepatitis C Patients. Annals of African Medicine 22:4, pages 456-464.
Crossref
Crossref
Seham Mahrous Zaki, Hanan Samir Ahmed, Monkez Motieh Yousif & Eman Mohamed Awad. (2022) Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients. Tropical Medicine and Infectious Disease 7:9, pages 230.
Crossref
Crossref
Mohamed Alhefnawy, Ahmed Mohey, Ahmed Fathi, Ahmed Mansour, Sherief Abd-Elsalam, Ahmed Eissa, Ayman Hagras, Stefano Puliatti & Khaled Almekaty. (2022) Effect of Direct-Acting Antiviral Drugs on Erectile Functions among Hepatitis
C Patients: A Prospective Interventional Study. Endocrine, Metabolic & Immune Disorders - Drug Targets 22:3, pages 310-317.
Crossref
Crossref
Tamer A. Elbedewy, Sherief Abd-Elsalam, Sahar Mohamed Mostafa, Raghda Samir Abdellatif, Amina Fouad, Mona Youssef, Yousry Esam-Eldin Abo-Amer & Mohamed A. Elsebaey. (2022) Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in
Adult Patients with β- Thalassemia Major: A Real-Life Study. Endocrine, Metabolic & Immune Disorders - Drug Targets 22:3, pages 290-296.
Crossref
Crossref
Gina Gamal Naguib, Amir Farid, Mohamed Hassan, Ahmed Elshafie, Yehia El Shazly, Mohamed Kamal Shaker, Haitham Ezzat, Eslam Safwat, Ossama Ashraf Ahmed, Hany Dabbous, Ahmed Fouad Sherief, Mohamed Hassany, Magdy Elserafy & Manal Hamdy Elsayed. (2021) Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience. Arab Journal of Gastroenterology 22:4, pages 285-291.
Crossref
Crossref
Gina Gamal Naguib, Tari George Michael, Yehia Elshazly, Maha Magdy Wahdan, Aya Mostafa, Ossama Ashraf Ahmed, Hany Dabbous, Heba Ismail Saad Aly, Mohamed Kamal Shaker, Hosam Samir Elbaz, Magdy El-Serafy, Wahid Doss, Sherief Abd-Elsalam & Manal Hamdy El-Sayed. (2021) The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. VirusDisease 32:3, pages 582-588.
Crossref
Crossref
Saad Alghamdi & Waleed Al-hamoudi. 2021. Advances in Hepatology. Advances in Hepatology.
Salma Sultan, Mohammed El-Mowafy, Abdelaziz Elgaml, Mohamed El-Mesery, Ahmed El Shabrawi, Mohamed Elegezy, Riadh Hammami & Walid Mottawea. (2020) Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection. ACS Infectious Diseases 7:5, pages 1059-1068.
Crossref
Crossref
Samah M. Alian, Mohamed Othman Wahba, Ahmed Fathy Gomaa & Sahar S. Khalil. (2020) The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis. Egyptian Rheumatology and Rehabilitation 47:1.
Crossref
Crossref
Sherin Zakaria & Alaa E. El-Sisi. (2020) Daclatasvir and Sofosbuvir Mitigate Hepatic Fibrosis Through Downregulation of TNF-α / NF-κB Signaling Pathway. Current Molecular Pharmacology 13:4, pages 318-327.
Crossref
Crossref
Eman Mohammed Helal, Mohamed Sharaf-Eldin, Abdel Raouf Abou El Azm, Nagwa Mansour Badr Eldin, Mohammed Mahmoud Dawoud, Sherief Abd-Elsalam & Dina Hazem Ziada. (2020) Hemodynamic Changes of Hepatic & Renal Vessels in Systemic Bacterial Infection with Fever in HCV Related Cirrhosis. Infectious Disorders - Drug Targets 20:4, pages 511-516.
Crossref
Crossref
Ghada M. Salum, Reham M. Dawood, Mai Abd el-Meguid, Noha E. Ibrahim, Ashraf O. Abdel Aziz & Mostafa K. El Awady. (2020) Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients. Genes & Diseases 7:3, pages 392-400.
Crossref
Crossref
Hany M. Elsadek, Elsayed S. Abdelbaser, Mohamed H. Emara, Hanan H. Soliman & Alaa A. Farag. (2020) Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. European Journal of Gastroenterology & Hepatology 32:8, pages 1046-1053.
Crossref
Crossref
Yousry Esam-Eldin Abo-amer, Rehab Badawi, Mohamed El-Abgeegy, Heba Fadl Elsergany, Ahmed Abdelhaleem Mohamed, Sahar Mohamed Mostafa, Hatem Samir Alegaily, Shaimaa Soliman, Sally Elnawasany & Sherief Abd-Elsalam. (2020) Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Advances in Virology 2020, pages 1-6.
Crossref
Crossref
Hassan Yousef Zied, Nashwa Mohamed Abo Alnasr, Amal Said El-Bendary, Sherief Abd-Elsalam & Rasha Youssef Hagag. (2020) Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14:4, pages 679-682.
Crossref
Crossref
Ebada Mohamed Said, Badawy A. Abdulaziz, Mohamed El Kassas, Ibrahim Hussein El Attar, Mohammed Emadeldeen & Sherief M. Abd-Elsalam. (2020) RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Archives of Virology 165:7, pages 1633-1639.
Crossref
Crossref
Abdel‐Hameed Ibrahim Mohammed Ebid, Osama Ashraf Ahmed, Sara Hassan Agwa, Sara Mohamed Abdel‐Motaleb, Amira Mohamed Elsawy & Radwa Samir Hagag. (2019) Safety, efficacy and cost of two direct‐acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients. Journal of Clinical Pharmacy and Therapeutics 45:3, pages 539-546.
Crossref
Crossref
Amal Ahmed Mohamed, Naglaa El-Toukhy Ramadan El-Toukhy, Ebada Mohamed Said, Hoda Mohamed Rabie Gabal, Hossameldin AbdelAziz, Wahid Doss, Hadeel El-Hanafi, Hala H. El Deeb, Seham Mahmoud, Mahmoud Elkadeem, Hassan Salama Shalby & Sherief Abd-Elsalam. (2020) Hepatitis C Virus: Efficacy of New DAAs Regimens. Infectious Disorders - Drug Targets 20:2, pages 143-149.
Crossref
Crossref
Hanan Soliman, Dina Ziada, Marwa Salama, Manal Hamisa, Rehab Badawi, Nehad Hawash, Amal Selim & Sherief Abd-Elsalam. (2020) Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study. Endocrine, Metabolic & Immune Disorders - Drug Targets 20:1, pages 104-111.
Crossref
Crossref
Amany M. Abo-Elenein, Maaly M. Mabrouk, Sabry Abou-Saif, Ola M. Saeed, Samy Khodeir, Mahmoud Elkadeem, Heba Elashry, Tamer Haydara, Mariam S. Zaghloul, Waseem M. Seleem, Samah A. Elshweikh & Sherief Abd-Elsalam. (2020) Role of Both Protein C and Antithrombin III as Predictors of Stage of Liver Disease in Chronic Viral Hepatitis B or C Infected Patients. Endocrine, Metabolic & Immune Disorders - Drug Targets 20:1, pages 112-117.
Crossref
Crossref
Sherief Abd-Elsalam, Yousry Esam-Eldin Abo-Amer, Mohamed El-Abgeegy, Samah A. Elshweikh, Heba Fadl Elsergany, Rehab Ahmed, Mahmoud Elkadeem, Nehad Hawash, Shaimaa Soliman, Rehab Badawi, Ayman Mohammed Abdou Elguindy, Moataz Yousry Soliman, Ahmed Abdelhaleem Mohmed & Loai Mansour. (2020) Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease. Medicine 99:42, pages e21972.
Crossref
Crossref
Rehab Badawi, Mohamed Alboraie, Sherief Abd-Elsalam, Mohamed Z. Abourahma, Haidi K. Ramadan, Ossama A. Ahmed, Mohamed H.A. Fouad, Shaimaa Soliman, Dina A. Mohareb, Tamer Haydara, Sherein M. Alnabawy & Mohamed El kassas. (2019) Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in Egypt. Endocrine, Metabolic & Immune Disorders - Drug Targets 19:7, pages 1005-1011.
Crossref
Crossref
Justine Umutesi, Carol Yingkai Liu, Michael J Penkunas, Jean Damascene Makuza, Corneille K Ntihabose, Sabine Umuraza, Julienne Niyikora, Janvier Serumondo, Neil Gupta & Sabin Nsanzimana. (2019) Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population. BMJ Open 9:7, pages e029743.
Crossref
Crossref
Tawhida Y. Abdel Ghaffar, Suzan El Naghi, Manal Abdel Gawad, Sarah Helmy, Aisha Abdel Ghaffar, Medhat Yousef & Mohamad Moafy. (2018) Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. Journal of Viral Hepatitis 26:2, pages 263-270.
Crossref
Crossref
Alaa E. El-Sisi & Sherin Zakaria. (2019) Potential Anti-Fibrotic Effect of Direct Acting Antiviral Drugs on CCl4 Induced Hepatic Fibrosis in Rats. Egyptian Journal of Basic and Clinical Pharmacology 9.
Crossref
Crossref
Dalia Omran, Mohamed Alboraie, Rania A Zayed, Mohamed-Naguib Wifi, Mervat Naguib, Mohamed Eltabbakh, Mohamed Abdellah, Ahmed Fouad Sherief, Sahar Maklad, Heba Hamdy Eldemellawy, Omar Khalid Saad, Doaa Mohamed Khamiss & Mohamed El Kassas. (2018) Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World Journal of Gastroenterology 24:38, pages 4330-4340.
Crossref
Crossref